TransCode Therapeutics
RNAZ
0 hedge funds and large institutions have $3.14M invested in TransCode Therapeutics in 2022 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
48% less capital invested
Capital invested by funds: $5.98M → $3.14M (-$2.84M)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$3.23M |
| 2 |
HNWAG
High Net Worth Advisory Group
Naples,
Florida
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WVP
1
Worth Venture Partners
Fort Lee,
New Jersey
| $934K | – | – | – |
|
|
KC
2
Kepos Capital
New York
| $792K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $576K | – | – | – |
|
|
RAM
4
Redmond Asset Management
Henrico,
Virginia
| $262K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $205K | – | – | – |
|
|
ACM
6
ACT Capital Management
Wayne,
Pennsylvania
| $144K | – | – | – |
|
7
State Street
Boston,
Massachusetts
| $61K | – | – | – |
|
|
KJHP
8
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| $58K | – | – | – |
|
9
BlackRock
New York
| $46K | – | – | – |
|
|
SC
10
Shay Capital
New York
| $43K | – | – | – |
|
11
UBS Group
Zurich,
Switzerland
| $11K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $6K | – | – | – |
|
|
ACM
13
AIGH Capital Management
Baltimore,
Maryland
| – | -$3.23M | -2 | Closed |
|
|
HNWAG
14
High Net Worth Advisory Group
Naples,
Florida
| – | -$6K | – | – |
|
RNAZ Hedge Fund Activity: Q1 2022 in Review
0 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q1 2022, worth a combined $3.14M — down 48% from $5.98M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RNAZ and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was AIGH Capital Management, exiting entirely with an estimated $3.23M sold.
- 0 institutional investors held TransCode Therapeutics (RNAZ) as of Q1 2022, down from 1 in Q4 2021.
- Funds reported $3.14M of TransCode Therapeutics stock for Q1 2022, down 48% quarter-over-quarter.
- 0 funds opened new TransCode Therapeutics positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest TransCode Therapeutics seller in Q1 2022 was AIGH Capital Management, an estimated $3.23M sold.
Based on aggregated 13F filings for Q1 2022.